Biofrontera Inc. (BFRI)
NASDAQ: BFRI · Real-Time Price · USD
1.120
-0.010 (-0.88%)
At close: Apr 28, 2026, 4:00 PM EDT
1.105
-0.015 (-1.34%)
After-hours: Apr 28, 2026, 6:27 PM EDT
Company Description
Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States.
It offers Ameluz, BF-RhodoLED, RhodoLED XL lamp series, and RhodoLED Lamps, which are used for the treatment of actinic keratosis, which are pre-cancerous skin lesions.
The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.
Biofrontera Inc.
| Country | United States |
| Founded | 1997 |
| IPO Date | Oct 29, 2021 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 94 |
| CEO | Hermann Luebbert |
Contact Details
Address: 660 Main Street, 1st Floor Woburn, Massachusetts 01801 United States | |
| Phone | 781 245 1325 |
| Website | biofrontera-us.com |
Stock Details
| Ticker Symbol | BFRI |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $5.00 |
| CIK Code | 0001858685 |
| CUSIP Number | 09077D100 |
| ISIN Number | US09077D2099 |
| Employer ID | 47-3765675 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Hermann Luebbert Ph.D. | Chief Executive Officer, President and Chairman |
| Eugene Frederick Leffler III | Chief Financial Officer |
| Erica F. Gates CPA, M.B.A. | Senior Director of Finance and Principal Accounting Officer |
| Jon Lyons M.B.A., Ph.D. | Vice President of Scientific and Medical Affairs |
| Daniel Hakansson J.D. | Senior Corporate Counsel |
| Samantha Widdicombe | Senior Vice President of Sales and Marketing |
| George P. Jones | Chief Commercial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 19, 2026 | 10-K | Annual Report |
| Mar 19, 2026 | 8-K | Current Report |
| Mar 9, 2026 | 8-K | Current Report |
| Feb 26, 2026 | 8-K | Current Report |
| Feb 11, 2026 | SCHEDULE 13G/A | Filing |
| Feb 9, 2026 | 8-K | Current Report |
| Jan 28, 2026 | SCHEDULE 13G/A | Filing |
| Jan 13, 2026 | 8-K | Current Report |
| Jan 7, 2026 | 8-K | Current Report |
| Dec 19, 2025 | EFFECT | Notice of Effectiveness |